Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients. However, acquired resistance to EGFR-TKIs is widely detected across the world, and the exact mechanisms have not been fully demonstrate...

Full description

Bibliographic Details
Main Authors: Jinrong Liao, Jinghui Lin, Dong Lin, Changyan Zou, Jessica Kurata, Renjang Lin, Zhiyong He, Ying Su
Format: Article
Language:English
Published: Nature Publishing Group 2017-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-017-00901-6

Internet

https://doi.org/10.1038/s41598-017-00901-6

Similar Items